Thromboprophylaxis for Coagulopathy Related to COVID-19 in Pediatrics: A Narrative Review

4Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

In addition to harming the respiratory system, COVID-19 can affect multiple organs. Children may develop a specific complication of COVID-19 called multisystem inflammatory syndrome in children (MIS-C) which could influence the vascular system of children and cause multiple coagulopathies in the body. Information on the use of thromboprophylaxis in this condition was collected via the review of various articles. In general, different factors in immune system responses can trigger the initiation of thrombotic events. Studies have shown that starting anticoagulant prophylaxis, which contributes to decreased thrombotic events, is dependent on the patient's condition and D-dimer levels. However, further studies on pediatric populations are needed to establish the role of anticoagulants in children with this condition.

Cite

CITATION STYLE

APA

Sahrai, H., Hemmati-Ghavshough, M., Shahrabi, M., Jafari-Rouhi, A. H., & Solduzian, M. (2023, July 1). Thromboprophylaxis for Coagulopathy Related to COVID-19 in Pediatrics: A Narrative Review. Pediatric Drugs. Adis. https://doi.org/10.1007/s40272-023-00566-x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free